UroGen Pharma Ltd. Other Income and Expense
UroGen Pharma Ltd. (URGN) reported Other Income and Expense of -$347.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:NonoperatingIncomeExpense · last filed 2026-08-05
- UroGen Pharma Ltd. nonoperating income (expense) for the quarter ending 2026-06-30 was -$347.00K.
- UroGen Pharma Ltd. nonoperating income (expense) for the quarter ending 2026-03-31 was -$323.00K.
- UroGen Pharma Ltd. nonoperating income (expense) for the quarter ending 2025-12-31 was -$5.00K.
- UroGen Pharma Ltd. nonoperating income (expense) for the quarter ending 2025-09-30 was -$197.00K.
- UroGen Pharma Ltd. nonoperating income (expense) for fiscal 2025 was -$670.00K.
- UroGen Pharma Ltd. nonoperating income (expense) for fiscal 2024 was -$229.00K, a 127.33% decline from fiscal 2023.
- UroGen Pharma Ltd. nonoperating income (expense) for fiscal 2023 was $838.00K, a 1063.89% increase from fiscal 2022.
- UroGen Pharma Ltd. nonoperating income (expense) for fiscal 2022 was $72.00K.
| Period end | Nonoperating Income (Expense) 3 month | Nonoperating Income (Expense) 3 month as first filed | Nonoperating Income (Expense) 6 month | Nonoperating Income (Expense) 9 month | Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$347.00K 10-Q · filed 2026-08-05 | -$670.00K 10-Q · filed 2026-08-05 | -$675.00K derived: sum of 3 quarters · filed 2026-08-05 | -$872.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2026-03-31 | -$323.00K 10-Q · filed 2026-05-06 | -$328.00K derived: sum of 2 quarters · filed 2026-05-06 | -$525.00K derived: sum of 3 quarters · filed 2026-05-06 | -$903.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-12-31 | -$5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$202.00K derived: sum of 2 quarters · filed 2026-03-02 | -$580.00K derived: sum of 3 quarters · filed 2026-08-05 | -$670.00K 10-K · filed 2026-03-02 | |
| 2025-09-30 | -$197.00K 10-Q · filed 2025-11-06 | -$575.00K derived: sum of 2 quarters · filed 2026-08-05 | -$665.00K 10-Q · filed 2025-11-06 | -$727.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-06-30 | -$378.00K 10-Q · filed 2026-08-05 | -$468.00K 10-Q · filed 2026-08-05 | -$530.00K derived: sum of 3 quarters · filed 2026-08-05 | -$688.00K derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | -$90.00K 10-Q · filed 2026-05-06 | -$152.00K derived: sum of 2 quarters · filed 2026-05-06 | -$310.00K derived: sum of 3 quarters · filed 2026-05-06 | -$136.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | -$62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$220.00K derived: sum of 2 quarters · filed 2026-03-02 | -$46.00K derived: sum of 3 quarters · filed 2026-03-02 | -$229.00K 10-K · filed 2026-03-02 | |
| 2024-09-30 | -$158.00K 10-Q · filed 2025-11-06 | $16.00K derived: sum of 2 quarters · filed 2025-11-06 | -$167.00K 10-Q · filed 2025-11-06 | $645.00K derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $174.00K 10-Q · filed 2025-08-07 | -$14.00K 10-Q · filed 2024-08-13 | -$9.00K 10-Q · filed 2025-08-07 | $803.00K derived: sum of 3 quarters · filed 2025-08-07 | $874.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$183.00K 10-Q · filed 2025-05-12 | $629.00K derived: sum of 2 quarters · filed 2025-05-12 | $700.00K derived: sum of 3 quarters · filed 2025-05-12 | $670.00K derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | $812.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $883.00K derived: sum of 2 quarters · filed 2025-03-10 | $853.00K derived: sum of 3 quarters · filed 2025-03-10 | $838.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $71.00K 10-Q · filed 2024-11-06 | $41.00K derived: sum of 2 quarters · filed 2024-11-06 | $26.00K 10-Q · filed 2024-11-06 | -$37.00K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$30.00K 10-Q · filed 2024-08-13 | -$45.00K 10-Q · filed 2024-08-13 | -$108.00K derived: sum of 3 quarters · filed 2024-08-13 | -$71.00K derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | -$15.00K 10-Q · filed 2024-05-13 | -$78.00K derived: sum of 2 quarters · filed 2024-05-13 | -$41.00K derived: sum of 3 quarters · filed 2024-05-13 | $61.00K derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | -$63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$26.00K derived: sum of 2 quarters · filed 2024-03-14 | $76.00K derived: sum of 3 quarters · filed 2024-03-14 | $72.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $37.00K 10-Q · filed 2023-11-14 | $139.00K derived: sum of 2 quarters · filed 2023-11-14 | $135.00K 10-Q · filed 2023-11-14 | $58.00K derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $98.00K 10-Q · filed 2023-08-10 | $21.00K derived: sum of 3 quarters · filed 2023-08-10 | $5.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$4.00K 10-Q · filed 2023-05-11 | -$81.00K derived: sum of 2 quarters · filed 2023-05-11 | -$97.00K derived: sum of 3 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | -$93.00K derived: sum of 2 quarters · filed 2023-03-24 | -$153.00K 10-K · filed 2023-03-24 | ||
| 2021-09-30 | -$16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$76.00K 10-Q · filed 2022-11-10 | |||
| 2021-06-30 | -$60.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |